-
Novel Risk Scoring System for Immune Checkpoint Inhibitors Treatment in Non-Small Cell Lung Cancer
Learn more about this newly developed scoring system for the risk stratification of NSCLC patients treated with immune checkpoint inhibitors.
May 13, 2021
-
Narrative Review of Lung Cancer Treatment at the Time of COVID-19 Pandemia
In what ways has the COVID-19 pandemic impacted the care of lung cancer patients?
May 06, 2021
-
Association Between Dietary Sodium, Potassium Intake and Lung Cancer Risk
What role might dietary sodium and potassium intake have in the risk for developing lung cancer?
April 29, 2021
-
Expert Consensus on Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
A new expert consensus provides guidance regarding the use of neoadjuvant immunotherapy in NSCLC.
April 22, 2021
-
Survival Benefit and Toxicity Profile of Adjuvant Icotinib for Patients With EGFR Mutation-Positive Non-Small Cell Lung Carcinoma
Might the use of adjuvant icotinib improve survival among EGFR mutation-positive NSCLC patients? What do we know about the treatment-related toxicities?
April 15, 2021
-
A Narrative Review of Lung Cancer Cytology in the Times of Coronavirus
Cytopathology plays a key role in the diagnosis and management of lung cancer. In what ways has the current pandemic impacted the handling and processing of these samples?
February 04, 2021
-
Treatments for Combined Small Cell Lung Cancer Patients
Which treatment strategies should be considered for this rare subtype of small cell lung cancer?
January 04, 2021
-
Recent Trends in Use of Adjuvant Chemotherapy in Elderly Stage II-III Non-Small Cell Lung Cancer
A new study examined recent trends in the patterns of use of adjuvant chemotherapy among elderly patients with lung cancer. What have we learned?
December 04, 2020
-
Uniportal Video-Assisted Thoracic Surgery for the Treatment of Lung Cancer
Should this procedure have a role in the treatment of lung cancer? A new consensus statement provides guidance and recommendations.
November 05, 2020
-
Integrating Clinical and Biological Prognostic Biomarkers in Patients With Advanced NSCLC Treated With Immunotherapy
What can these potential biomarkers tell us about the prognosis of immunotherapy-treated non-small cell lung cancer?
October 05, 2020
-
Role of Chest Radiographs in Early Lung Cancer Detection
Low-dose CT is traditionally used in the screening of patients at risk for lung cancer, but it has its limitations. Might chest radiography provide a viable alternative?
September 04, 2020
-
Feasibility and Safety of PD-1/L1 Inhibitors for Non-Small Cell Lung Cancer in Front-Line Treatment
Are PD-1/L1 inhibitors a safe and effective option for the front line treatment of patients with advanced non-small cell lung cancer?
August 07, 2020
-
Challenges and Countermeasures of Thoracic Oncology in the Epidemic of COVID-19
The COVID-19 epidemic has posed unique challenges to the diagnosis and treatment of cancer patients. Find out how the field of thoracic oncology is impacted.
July 08, 2020
-
Frontiers of ctDNA, Targeted Therapies, and Immunotherapy in Non-Small-Cell Lung Cancer
From ctDNA detection to immunotherapy and targeted therapies -- learn about the latest frontiers in non-small-cell lung cancer.
June 08, 2020
-
Endocrine Adverse Events Related to Immune-Oncology Agents
Learn more about the endocrine-related adverse events associated with the use of immune-oncology agents and how these toxicities should be managed.
May 08, 2020
-
Toxicity of Tumor Immune Checkpoint Inhibitors
Are you aware of the potential adverse events associated with immune checkpoint inhibitors? Find out how to identify and manage these toxic effects.
March 03, 2020
-
Society for Translational Medicine Consensus on Postoperative Management of EGFR-Mutant Lung Cancer (2019 Edition)
Consensus-based recommendations from the Society for Translational Medicine addresses the management of EGFR-mutated lung cancer.
February 03, 2020
-
Is Lowering the PD-L1 Threshold for First-Line Pembrolizumab Monotherapy a Good Idea?
What is the best treatment option for patients with advanced NSCLC and PD-L1 of 1-49% on tumor cells?
January 02, 2020
-
Current Perspectives on Statins as Potential Anti-Cancer Therapeutics
Which molecular mechanisms may drive the anticancer effects of statins?
December 03, 2019
-
Influence and Mechanism of Lung Cavitation Development on Antiangiogenic Therapy
Is development of lung cavitation following apatinib therapy for lung cancer associated with better outcomes?
November 06, 2019
